Search

Your search keyword '"Palova, Hana"' showing total 21 results
Start Over Author "Palova, Hana"
21 results on '"Palova, Hana"'

1. Diagnostic efficacy and clinical utility of whole-exome sequencing in Czech pediatric patients with rare and undiagnosed diseases

Author

Slaba, Katerina, Pokorna, Petra, Jugas, Robin, Palova, Hana, Prochazkova, Dagmar, Aulicka, Stefania, Spanelova, Klara, Danhofer, Pavlina, Horak, Ondrej, Tuckova, Jana, Kleiblova, Petra, Gaillyova, Renata, Hrunka, Matej, Jouza, Martin, Pinkova, Blanka, Papez, Jan, Konecna, Petra, Zidkova, Jana, Stourac, Petr, Sterba, Jaroslav, Demlova, Regina, Demlova, Eva, Jabandziev, Petr, and Slaby, Ondrej

Published
2024
Full Text
View/download PDF

2. Precision immuno-oncology approach for four malignant tumors in siblings with constitutional mismatch repair deficiency syndrome

Author

Palova, Hana, Das, Anirban, Pokorna, Petra, Bajciova, Viera, Pavelka, Zdenek, Jezova, Marta, Pal, Karol, Dimayacyac, Jose R., Negm, Logine, Stengs, Lucie, Bianchi, Vanessa, Vejmelkova, Klara, Noskova, Kristyna, Jarosova, Marie, Mejstrikova, Sona, Mudry, Peter, Kyr, Michal, Merta, Tomas, Tinka, Pavel, Drabova, Klara, Aulicka, Stefania, Jugas, Robin, Tabori, Uri, Slaby, Ondrej, and Sterba, Jaroslav

Published
2024
Full Text
View/download PDF

3. Real-World Performance of Integrative Clinical Genomics in Pediatric Precision Oncology

Author

Pokorna, Petra, Palova, Hana, Adamcova, Sona, Jugas, Robin, Al Tukmachi, Dagmar, Kyr, Michal, Knoflickova, Dana, Kozelkova, Katerina, Bystry, Vojtech, Mejstrikova, Sona, Merta, Tomas, Trachtova, Karolina, Podlipna, Eliska, Mudry, Peter, Pavelka, Zdenek, Bajciova, Viera, Tinka, Pavel, Jarosova, Marie, Catela Ivkovic, Tina, Madlener, Sibylle, Pal, Karol, Stepien, Natalia, Mayr, Lisa, Tichy, Boris, Drabova, Klara, Jezova, Marta, Kozakova, Sarka, Vanackova, Jitka, Radova, Lenka, Steininger, Karin, Haberler, Christine, Gojo, Johannes, Sterba, Jaroslav, and Slaby, Ondrej

Published
2024
Full Text
View/download PDF

6. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location

Author

Liu, Ilon, Jiang, Li, Samuelsson, Erik R., Marco Salas, Sergio, Beck, Alexander, Hack, Olivia A., Jeong, Daeun, Shaw, McKenzie L., Englinger, Bernhard, LaBelle, Jenna, Mire, Hafsa M., Madlener, Sibylle, Mayr, Lisa, Quezada, Michael A., Trissal, Maria, Panditharatna, Eshini, Ernst, Kati J., Vogelzang, Jayne, Gatesman, Taylor A., Halbert, Matthew E., Palova, Hana, Pokorna, Petra, Sterba, Jaroslav, Slaby, Ondrej, Geyeregger, Rene, Diaz, Aaron, Findlay, Izac J., Dun, Matthew D., Resnick, Adam, Suvà, Mario L., Jones, David T. W., Agnihotri, Sameer, Svedlund, Jessica, Koschmann, Carl, Haberler, Christine, Czech, Thomas, Slavc, Irene, Cotter, Jennifer A., Ligon, Keith L., Alexandrescu, Sanda, Yung, W. K. Alfred, Arrillaga-Romany, Isabel, Gojo, Johannes, Monje, Michelle, Nilsson, Mats, and Filbin, Mariella G.

Published
2022
Full Text
View/download PDF

7. Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high‐risk pediatric cancer patients.

Author

Kyr, Michal, Mudry, Peter, Polaskova, Kristyna, Dubska, Lenka Zdrazilova, Demlova, Regina, Kubatova, Jana, Hlavackova, Eva, Pilatova, Katerina Cerna, Mazanek, Pavel, Vejmelkova, Klara, Dusek, Vitezslav, Tinka, Pavel, Balaz, Martin, Merta, Tomas, Kuttnerova, Zuzana, Turekova, Terezia, Pavelka, Zdenek, Pokorna, Petra, Palova, Hana, and Mlnarikova, Marie

Subjects
VACCINE effectiveness, CANCER vaccines, COMBINED modality therapy, VACCINATION of children, DENDRITIC cells
Abstract

A lot of hope for high‐risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single‐agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high‐risk solid tumors using the N‐of‐1 approach in real‐world scenario. A total of 160 evaluable events occurred in 48 patients during the 4‐year follow‐up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P =.048) or in patients with disease control (HR = 0.16, P =.00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P =.225). A strong synergistic effect was found for immune check‐point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P =.0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Diagnostic yield and clinical utility of whole-exome sequencing in pediatric patients with rare and undiagnosed diseases: a prospective, single-center study from the Czech Republic

Author

Slaba, Katerina, primary, Pokorna, Petra, additional, Jugas, Robin, additional, Palova, Hana, additional, Prochazkova, Dagmar, additional, Aulicka, Stefania, additional, Danhofer, Pavlina, additional, Horak, Ondrej, additional, Tuckova, Jana, additional, Kleiblova, Petra, additional, Gailyova, Renata, additional, Hrunka, Matej, additional, Jouza, Martin, additional, Pinkova, Blanka, additional, Papez, Jan, additional, Konecna, Petra, additional, Zidkova, Jana, additional, Stourac, Petr, additional, Sterba, Jaroslav, additional, Demlova, Regina, additional, Demlova, Eva, additional, Jabandziev, Petr, additional, and Slaby, Ondrej, additional

Published
2024
Full Text
View/download PDF

10. Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Author

Pokorna, Petra, Lakka Klement, Giannoula, Vasikova, Alzbeta, Kanderova, Veronika, Jezova, Marta, Noskova, Kristyna, Mudry, Peter, Kyr, Michal, Merta, Tomas, Bajciova, Viera, Krenova, Zdenka, Palova, Hana, Valik, Dalibor, Zdrazilova Dubska, Lenka, Slaby, Ondrej, and Sterba, Jaroslav

Published
2022
Full Text
View/download PDF

11. DDDR-17. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS

Author

Mayr, Lisa, primary, Trissal, Maria, additional, Schwark, Kallen, additional, Neyazi, Sina, additional, Beck, Alexander, additional, Labelle, Jenna, additional, Marques, Joana Graca, additional, Weiler-Wichtl, Liesa, additional, Madlener, Sibylle, additional, Kong, Seongbae, additional, Miclea, Madeline, additional, Supko, Jeffrey, additional, Guntner, Armin Sebastian, additional, Palova, Hana, additional, Neradil, Jakub, additional, Stepien, Natalia, additional, Loetsch-Gojo, Daniela, additional, Dorfer, Christian, additional, Dieckmann, Karen, additional, Peyrl, Andreas, additional, Azizi, Amedeo A, additional, Baumgartner, Alicia-Christina, additional, Slaby, Ondrej, additional, Pokorna, Petra, additional, Dubois, Frank, additional, Greenwald, Noah, additional, Bandopadhayay, Pratiti, additional, Beroukhim, Rameen, additional, Ligon, Keith, additional, Kramm, Christof, additional, Bronsema, Annika, additional, Bailey, Simon, additional, Stuecklin, Ana Guerreiro, additional, Mueller, Sabine, additional, Skrypek, Mary, additional, Martinez, Nina, additional, Bowers, Daniel C, additional, Jones, David, additional, Jones, Chris, additional, Jaeger, Natalie, additional, Sterba, Jaroslav, additional, Müllauer, Leonhard, additional, Haberler, Christine, additional, Kumar-Sinha, Chandan, additional, Chinnaiyan, Arul, additional, Mody, Rajen, additional, Furtner-Srajer, Julia, additional, Koschmann, Carl, additional, Gojo, Johannes, additional, and Filbin, Mariella, additional

Published
2023
Full Text
View/download PDF

12. Abstract 1063: Precision medicine and cancer drug repurposing in the management of vascular anomalies

Author

Pokorna, Petra, primary, Faberova, Renata, additional, Koskova, Olga, additional, Sterba, Martin, additional, Palova, Hana, additional, Kozelkova, Katerina, additional, Jugas, Robin, additional, Tukmachi, Dagmar Al, additional, Machackova, Tana, additional, Sana, Jiri, additional, Mudry, Peter, additional, Sterba, Jaroslav, additional, and Slaby, Ondrej, additional

Published
2023
Full Text
View/download PDF

13. Abstract 4511: Impact of the comprehensive genomic profiling on the individual therapeutic planning in high-risk/refractory tumors: real-world precision medicine in pediatric oncology

Author

Pokorna, Petra, primary, Palova, Hana, additional, Adamcova, Sona, additional, Bystry, Vojtech, additional, Kyr, Michal, additional, Tukmachi, Dagmar Al, additional, Mejstrikova, Sona, additional, Mudry, Peter, additional, Sterba, Jaroslav, additional, and Slaby, Ondrej, additional

Published
2023
Full Text
View/download PDF

15. EPCO-21. THE SPATIAL ORGANIZATION OF H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA

Author

Liu, Ilon, primary, Li, Jiang, additional, Samuelsson, Erik, additional, Salas, Sergio Marco, additional, Beck, Alexander, additional, Hack, Olivia, additional, Jeong, Daeun, additional, Shaw, McKenzie, additional, Englinger, Bernhard, additional, Labelle, Jenna, additional, Mire, Hafsa, additional, Madlener, Sibylle, additional, Mayr, Lisa, additional, Quezada, Michael, additional, Trissal, Maria, additional, Panditharatna, Eshini, additional, Ernst, Kati, additional, Gatesman, Taylor, additional, Halbert, Matthew, additional, Palova, Hana, additional, Pokorna, Petra, additional, Sterba, Jaroslav, additional, Slaby, Ondrej, additional, Geyeregger, Rene, additional, Diaz, Aaron, additional, Resnick, Adam C, additional, Suva, Mario, additional, Jones, David, additional, Agnihotri, Sameer, additional, Ostlin, Jessica, additional, Koschmann, Carl, additional, Haberler, Christine, additional, Czech, Thomas, additional, Slavc, Irene, additional, Cotter, Jennifer, additional, Ligon, Keith, additional, Alexandrescu, Sanda, additional, Yung, W K Alfred, additional, Arrillaga-Romany, Isabel, additional, Gojo, Johannes, additional, Monje, Michelle, additional, Nilsson, Mats, additional, and Filbin, Mariella, additional

Published
2022
Full Text
View/download PDF

16. DDDR-22. TRANSLATION OF THE PDGFRA/KIT INHIBITOR AVAPRITINIB FOR PEDIATRIC HIGH-GRADE GLIOMA

Author

Mayr, Lisa, primary, Trissal, Maria, additional, Schwark, Kallen, additional, Labelle, Jenna, additional, Kong, Seongbae, additional, Groves, Andrew, additional, Supko, Jeffrey, additional, Hack, Olivia, additional, Marques, Joana, additional, Panditharatna, Eshini, additional, Dubois, Frank, additional, Greenwald, Noah, additional, Bandopadhayay, Pratiti, additional, Ligon, Keith, additional, Furtner-Srajer, Julia, additional, Weiler-Wichtl, Liesa, additional, Leiss, Ulrike, additional, Rosenmayr, Verena, additional, Madlener, Sibylle, additional, Stepien, Natalia, additional, Lötsch-Gojo, Daniela, additional, Dorfer, Christian, additional, Dieckmann, Karin, additional, Azizi, Amedeo, additional, Guntner, Armin, additional, Palova, Hana, additional, Slaby, Ondrej, additional, Pokorná, Petra, additional, Beroukhim, Rameen, additional, Kramm, Christof, additional, Jones, David T, additional, Štěrba, Jaroslav, additional, Mullauer, Leonhard, additional, Haberler, Christine, additional, Perez, Nisha, additional, Kim, Sean, additional, Hsieh, Anthony, additional, Dimitrijevic, Sasa, additional, Skrypek, Mary, additional, Martinez, Nina, additional, Bowers, Daniel, additional, Filbin, Mariella, additional, Gojo, Johannes, additional, and Koschmann, Carl, additional

Published
2022
Full Text
View/download PDF

17. Risk factors for tumors or leukemia development in the first two years of life.

Author

Wiedermannova, Hana, Mudry, Peter, Pavlicek, Jan, Tomaskova, Hana, Hladikova, Andrea, Palova, Hana, Vesela, Petra, Slaby, Ondrej, and Sterba, Jaroslav

Abstract

Objectives. The objective of this study was to determine the incidence of neoplastic diseases and associated risk factors in the early stages of life. Methods. Data were retrospectively assessed in 730,000 live births between 2000 and 2019. The occurrence of tumors was monitored in the neonatal, infant (1--12 months), and toddler (13--24 months) periods. Risk factors were divided into demographic, internal, and environmental factors. The control group consisted of subjects in the same age category without oncological diseases. Results. A total of 452 neoplastic diseases were diagnosed in the study sample. In total, 24% (110/452) manifested during the neonatal period, 45% (203/452) in infants, and 31% (139/452) at the age of 13--24 months. Any genetic disease (OR 26.68; 95% CI 7.64--93.12) and medications used by the mother (OR 3.07; 95% CI 1.32--7.15) were identified as risk factors. Without adjustment for all factors, asphyxia in the first minute, a younger age of the mother, lower pregnancy, and the presence of a congenital defect manifested themselves as risk factors. Conclusions. The highest risk factors for the development of early childhood tumors were identified as with medications used by the mother before or during pregnancy and genetic diseases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Abstract 76: Comprehensive genomic profiling as an approach to guide therapeutic planning in pediatric patients with high-risk solid tumors

Author

Pokorna, Petra, primary, Palova, Hana, additional, Ivkovic, Tina Catela, additional, Adamcova, Sona, additional, Kyr, Michal, additional, Bystry, Vojtech, additional, Jugas, Robin, additional, Trachtova, Karolina, additional, Tukmachi, Dagmar Al, additional, Merta, Tomas, additional, Juracek, Jaroslav, additional, Sana, Jiri, additional, Mejstrikova, Sona, additional, Jezova, Marta, additional, Mudry, Peter, additional, Pavelka, Zdenek, additional, Sterba, Jaroslav, additional, and Slaby, Ondrej, additional

Published
2022
Full Text
View/download PDF

19. DIPG-60. Avapritinib for targeting PDGFRA in H3K27M – mutated diffuse midline glioma

Author

Mayr, Lisa, primary, Madlener, Sibylle, additional, Weiler-Wichtl, Liesa, additional, Rosenmayr, Verena, additional, Furtner-Srajer, Julia, additional, Guntner, Armin, additional, Stepien, Natalia, additional, Baumgartner, Alicia-Christina, additional, Dorfer, Christian, additional, Haberler, Christine, additional, Müllauer, Leonhard, additional, Palova, Hana, additional, Pokorna, Petra, additional, Sterba, Jaroslav, additional, Dieckmann, Karin, additional, Azizi, Amedeo, additional, Peyrl, Andreas, additional, Kim, Sean, additional, Hsieh, Antony, additional, Dimitrijevic, Sasa, additional, and Gojo, Johannes, additional

Published
2022
Full Text
View/download PDF

21. Spindle Cell Hemangioma and Atypically Localized Juxtaglomerular Cell Tumor in a Patient with Hereditary BRIP1 Mutation: A Case Report

Author

Papez, Jan, primary, Starha, Jiri, additional, Zerhau, Pavel, additional, Pavlovska, Denisa, additional, Jezova, Marta, additional, Jurencak, Tomas, additional, Slaba, Katerina, additional, Sterba, Martin, additional, Kerekes, Arpad, additional, Merta, Tomas, additional, Haluskova, Terezia, additional, Palova, Hana, additional, Slaby, Ondrej, additional, Sterba, Jaroslav, additional, and Jabandziev, Petr, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results